148 related articles for article (PubMed ID: 38519706)
21. Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer.
Seki H; Sakurai T; Sakurada A; Kinoshita T; Shimizu K
Anticancer Res; 2022 Feb; 42(2):1099-1106. PubMed ID: 35093912
[TBL] [Abstract][Full Text] [Related]
22. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
24. The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer.
Çetin K; Kökten Ş; Sarıkamış B; Yıldırım S; Gökçe ON; Barışık NÖ; Kılıç Ü
Breast Cancer Res Treat; 2024 May; 205(1):17-27. PubMed ID: 38273215
[TBL] [Abstract][Full Text] [Related]
25. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
Gavilá J; De La Haba J; Bermejo B; Rodríguez-Lescure Á; Antón A; Ciruelos E; Brunet J; Muñoz-Couselo E; Santisteban M; Rodríguez Sánchez CA; Santaballa A; Sánchez Rovira P; García Sáenz JÁ; Ruiz-Borrego M; Guerrero-Zotano AL; Huerta M; Cotes-Sanchís A; Lao Romera J; Aguirre E; Cortés J; Llombart-Cussac A
Clin Transl Oncol; 2020 Mar; 22(3):420-428. PubMed ID: 31203575
[TBL] [Abstract][Full Text] [Related]
26. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
27. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
28. Significance of baseline neutrophil-to-lymphocyte ratio for progression-free survival of patients with HER2-positive breast cancer treated with trastuzumab emtansine.
Imamura M; Morimoto T; Egawa C; Fukui R; Bun A; Ozawa H; Miyagawa Y; Fujimoto Y; Higuchi T; Miyoshi Y
Sci Rep; 2019 Feb; 9(1):1811. PubMed ID: 30755651
[TBL] [Abstract][Full Text] [Related]
29. Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuzumab emtansine treatment.
Watanuki R; Shimomura A; Yazaki S; Noda-Narita S; Sumiyoshi-Okuma H; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Yonemori K; Tamura K
Medicine (Baltimore); 2020 Sep; 99(38):e22331. PubMed ID: 32957402
[TBL] [Abstract][Full Text] [Related]
30. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
31. Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
[TBL] [Abstract][Full Text] [Related]
32. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.
Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z
BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715
[TBL] [Abstract][Full Text] [Related]
34. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
[TBL] [Abstract][Full Text] [Related]
35. Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E; Comaro E; Talamini R; Turchet E; Miolo G; Scalone S; Militello L; Lombardi D; Spazzapan S; Perin T; Massarut S; Crivellari D; Dolcetti R; Martorelli D
J Transl Med; 2015 Jun; 13():204. PubMed ID: 26116238
[TBL] [Abstract][Full Text] [Related]
36. Real-world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia.
Sun J; Zhong X; Ma J; Sun W; Han HS; Soliman HH; Loftus LS; Costa RLB; Armaghani AJ; Soyano-Muller AE; Czerniecki BJ; Lee MC; Kiluk JV; Khakpour N; Hoover SJ; Laronga C; Khong HT
Cancer Med; 2021 Nov; 10(21):7665-7672. PubMed ID: 34590788
[TBL] [Abstract][Full Text] [Related]
37. Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
Kaczmarek E; Saint-Martin C; Pierga JY; Brain E; Rouzier R; Savignoni A; Mouret-Fourme E; Dieras V; Piot I; Dubot C; Carton M; Lerebours F
Breast Cancer Res Treat; 2019 Dec; 178(3):505-512. PubMed ID: 31486993
[TBL] [Abstract][Full Text] [Related]
38. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
39. Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer.
Liu C; Hu Q; Hu K; Su H; Shi F; Kong L; Zhu H; Yu J
J Transl Med; 2019 Apr; 17(1):120. PubMed ID: 30971280
[TBL] [Abstract][Full Text] [Related]
40. Impact of early dose intensity reduction of Palbociclib on clinical outcomes in patients with hormone-receptor-positive metastatic breast cancer.
Moftakhar B; Lekkala M; Strawderman M; Smith TC; Meacham P; Fitzgerald B; Falkson CI; Dhakal A
Breast Cancer Res Treat; 2020 Sep; 183(2):411-418. PubMed ID: 32671612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]